U.s. department of justice informs viatris that it no longer considers mylan a subject of generic drug industry antitrust investigation

Pittsburgh , july 2, 2024 /prnewswire/ -- viatris inc. (nasdaq: vtrs) today announced that the antitrust division of the u.s. department of justice ("doj") has advised that it no longer considers mylan, and its former president, rajiv malik, a subject of its antitrust investigation in the generic drug industry. the civil division of the doj has also informed the company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.
VTRS Ratings Summary
VTRS Quant Ranking